This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
and you are
between 18 and 50
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The primary purpose of this study is to assess the ability of scopolamine to improve the antidepressant effects of ECT and to determine whether scopolamine will shorten the time to response and remission for patients receiving ECT. The hypothesis are: 1. Patients receiving ECT plus scopolamine will have greater improvement in depression symptoms than those receiving ECT plus placebo. 2. Patients receiving scopolamine in addition to ECT will require fewer ECT treatments to obtain response/remission compared to the group receiving ECT plus placebo. 3. Time to response and to remission in the scopolamine group will be significantly shorter compared to ECT alone.

Provided treatments

  • Drug: Scopolamine

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01312844. The sponsor of the trial is Massachusetts General Hospital and it is looking for 7 volunteers for the current phase.
Official trial title:
A Pilot Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)